Comparative cost-utility analysis of ixekizumab, tofacitinib, and golimumab in psoriatic arthritis: a real-world Markov model simulation
{{output}}
Background: Psoriatic arthritis (PsA) requires long-term, phenotype-oriented management. This study compared the cost-utility of ixekizumab, tofacitinib, and golimumab using a real-world modeling approach. ... ...
